BELITE BIO, INC (BLTE) Stock
6 of the hedge funds AlphaScala tracks reported BLTE in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $76.16M. Company insiders reported 0 open-market buys and 50 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own BLTE?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 495K | $76.16M | -13% |
| Maverick Capital Lee Ainslie | 396K | $61.03M | NEW |
| Citadel Ken Griffin | 186K | $28.67M | +9171% |
| Duquesne Family Office Stanley Druckenmiller | 106K | $16.34M | n/a |
| Renaissance Technologies Jim Simons (founder) | 56K | $8.59M | +7% |
| Point72 Steve Cohen | 51K | $7.88M | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are BELITE BIO, INC insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 1, 26 | Scholl Hendrik Peter | Chief Medical Officer | SELL | 200 | $33K |
| Oct 1, 26 | Scholl Hendrik Peter | Chief Medical Officer | SELL | 24 | $4K |
| Oct 1, 26 | Scholl Hendrik Peter | Chief Medical Officer | SELL | 120 | $20K |
| Oct 1, 26 | Scholl Hendrik Peter | Chief Medical Officer | SELL | 50 | $8K |
| Oct 1, 26 | Scholl Hendrik Peter | Chief Medical Officer | SELL | 78 | $13K |
| Oct 1, 26 | Scholl Hendrik Peter | Chief Medical Officer | SELL | 12 | $2K |
| Oct 1, 26 | Scholl Hendrik Peter | Chief Medical Officer | SELL | 14 | $2K |
| Oct 1, 26 | Scholl Hendrik Peter | Chief Medical Officer | SELL | 2 | $340 |
| Sep 8, 26 | Chuang Hao-Yuan | Chief Financial Officer | SELL | 2.2K | $427K |
| Sep 8, 26 | Chuang Hao-Yuan | Chief Financial Officer | SELL | 4.1K | $806K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →BLTE price chart
Powered by TradingViewWhat does BELITE BIO, INC do?
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing novel oral therapeutics for degenerative retinal diseases with significant unmet medical needs, including Stargardt disease type 1 and geographic atrophy in advanced dry age-related macular degeneration. Its lead product candidate, Tinlarebant (LBS-008), is an orally administered therapy in phase 3 clinical trials, such as the DRAGON, DRAGON II, and PHOENIX studies, targeting adolescent and adult patients to slow retinal lesion growth by inhibiting retinol-binding protein 4. The company has received regulatory designations including Breakthrough Therapy, Fast Track, Rare Pediatric Disease, and Orphan Drug, with applications accepted by agencies like China's NMPA and the UK's MHRA. Additionally, Belite Bio advances LBS-009, an oral anti-retinol-binding protein 4 therapy in preclinical development for liver diseases such as non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. Founded in 2016 and headquartered in San Diego, California, Belite Bio plays a key role in addressing vision loss through innovative small-molecule treatments.